Article: Celgene Corporation Reports Record Revenue and Operating Profits.

REVLIMID(R) and THALOMID(R) Regulatory Approvals Highlight Second Quarter Performance

Product Sales Drive Record Second Quarter Revenue and Profits:

- Total Net Product Sales Reached a Record $176.4 Million

- REVLIMID Achieved $63.0 Million in Net Product Sales

- THALOMID Net Product Sales Attained $107.2 Million

- Adjusted Second Quarter Earnings Per Diluted Share Increased to $0.11

Financial Highlights of Second Quarter Performance:

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!